BG63103B1 - Използуване на алендронат за профилактика на остеопороза - Google Patents

Използуване на алендронат за профилактика на остеопороза Download PDF

Info

Publication number: BG63103B1
Authority: BG; Bulgaria
Prior art keywords: alendronate; osteoporosis; bone; aln; placebo
Prior art date: 1995-06-02

Application number

BG102060A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG102060A (en

Inventor

Ashley Yates

Original Assignee

Merck & Co. Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-02

Filing date

1997-11-20

Publication date

2001-04-30

1997-11-20 Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.

1998-07-31 Publication of BG102060A publication Critical patent/BG102060A/xx

2001-04-30 Publication of BG63103B1 publication Critical patent/BG63103B1/bg

Links

OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 title claims abstract description 30
229940062527 alendronate Drugs 0.000 title claims abstract description 29
208000001132 Osteoporosis Diseases 0.000 title claims abstract description 19
230000002265 prevention Effects 0.000 title claims abstract description 8
238000000034 method Methods 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 9
150000004684 trihydrates Chemical group 0.000 claims description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
CAKRAHQRJGUPIG-UHFFFAOYSA-M sodium;[4-azaniumyl-1-hydroxy-1-[hydroxy(oxido)phosphoryl]butyl]-hydroxyphosphinate Chemical class [Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O CAKRAHQRJGUPIG-UHFFFAOYSA-M 0.000 claims 1
206010036601 premature menopause Diseases 0.000 abstract description 3
229940068196 placebo Drugs 0.000 description 18
239000000902 placebo Substances 0.000 description 18
210000000988 bone and bone Anatomy 0.000 description 14
235000002639 sodium chloride Nutrition 0.000 description 12
238000011282 treatment Methods 0.000 description 12
229940011871 estrogen Drugs 0.000 description 10
239000000262 estrogen Substances 0.000 description 10
-1 alkali metal salts Chemical class 0.000 description 8
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 5
239000000583 progesterone congener Substances 0.000 description 5
206010065687 Bone loss Diseases 0.000 description 4
206010017076 Fracture Diseases 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
229910052500 inorganic mineral Inorganic materials 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000011707 mineral Substances 0.000 description 4
235000010755 mineral Nutrition 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000037118 bone strength Effects 0.000 description 3
239000011575 calcium Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
208000010392 Bone Fractures Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000037182 bone density Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
239000000203 mixture Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
241000220479 Acacia Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
208000008924 Femoral Fractures Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
MPSOHXLZDRQABN-KOAPPJMKSA-N [(8r,9s,10r,13s,14s,17r)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;(8r,9s,13s,14s,16r,17 Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 MPSOHXLZDRQABN-KOAPPJMKSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
230000005800 cardiovascular problem Effects 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940035811 conjugated estrogen Drugs 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
201000003914 endometrial carcinoma Diseases 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
238000009164 estrogen replacement therapy Methods 0.000 description 1
VUCAHVBMSFIGAI-ZFINNJDLSA-M estrone sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 VUCAHVBMSFIGAI-ZFINNJDLSA-M 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
208000020694 gallbladder disease Diseases 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000003908 liver function Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
230000003821 menstrual periods Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000000025 natural resin Substances 0.000 description 1
229960001652 norethindrone acetate Drugs 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
230000001599 osteoclastic effect Effects 0.000 description 1
238000009527 percussion Methods 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
229940063238 premarin Drugs 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
CMDGQTVYVAKDNA-UHFFFAOYSA-N propane-1,2,3-triol;hydrate Chemical compound O.OCC(O)CO CMDGQTVYVAKDNA-UHFFFAOYSA-N 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229940063222 provera Drugs 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000001457 vasomotor Effects 0.000 description 1
229930195724 β-lactose Natural products 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BG102060A 1995-06-02 1997-11-20 Използуване на алендронат за профилактика на остеопороза BG63103B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US45819595A	1995-06-02	1995-06-02
PCT/US1996/007912 WO1996038156A1 (en)	1995-06-02	1996-05-29	Use of alendronate for the prevention of osteoporosis

Publications (2)

Publication Number	Publication Date
BG102060A BG102060A (en)	1998-07-31
BG63103B1 true BG63103B1 (bg)	2001-04-30

Family

ID=23819759

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG102060A BG63103B1 (bg)	1995-06-02	1997-11-20	Използуване на алендронат за профилактика на остеопороза

Country Status (21)

Country	Link
EP (1)	EP0828496A1 (ja)
JP (1)	JPH10506648A (ja)
KR (1)	KR19990022436A (ja)
CN (1)	CN1192685A (ja)
AU (1)	AU709196B2 (ja)
BG (1)	BG63103B1 (ja)
BR (1)	BR9609020A (ja)
CA (1)	CA2222318A1 (ja)
CZ (1)	CZ381197A3 (ja)
EA (1)	EA000677B1 (ja)
EE (1)	EE03306B1 (ja)
HU (1)	HUP9900659A3 (ja)
IL (1)	IL118422A0 (ja)
IS (1)	IS4617A (ja)
NO (1)	NO975527L (ja)
NZ (1)	NZ308935A (ja)
PL (1)	PL323669A1 (ja)
SK (1)	SK159597A3 (ja)
TR (1)	TR199701482T1 (ja)
WO (1)	WO1996038156A1 (ja)
ZA (1)	ZA964465B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010031244A1 (en)	1997-06-13	2001-10-18	Chiesi Farmaceutici S.P.A.	Pharmaceutical aerosol composition
SE9901272D0 (sv) *	1999-04-09	1999-04-09	Astra Ab	New improved formulation
KR100317935B1 (ko) *	1999-10-20	2001-12-22	유승필	대사성 골질환 치료용 약제조성물 및 이의 제조방법
BR0209360A (pt) *	2001-05-02	2004-06-08	Novartis Ag	Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
JP2010043119A (ja) *	2009-10-16	2010-02-25	Gador Sa	骨の代謝病の予防および／または治療のための組成物、その組成物の調製方法およびその使用
KR102472749B1 (ko) *	2022-01-18	2022-12-02	주식회사 위엔씨	유해가스제거 및 항균탈취기능을 함유한 흡착소재 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5366965A (en) *	1993-01-29	1994-11-22	Boehringer Mannheim Gmbh	Regimen for treatment or prophylaxis of osteoporosis
US5462932A (en) *	1994-05-17	1995-10-31	Merck & Co., Inc.	Oral liquid alendronate formulations

1996
- 1996-05-27 IL IL11842296A patent/IL118422A0/xx unknown
- 1996-05-29 CN CN96196075A patent/CN1192685A/zh active Pending
- 1996-05-29 WO PCT/US1996/007912 patent/WO1996038156A1/en not_active Ceased
- 1996-05-29 TR TR97/01482T patent/TR199701482T1/xx unknown
- 1996-05-29 JP JP8536616A patent/JPH10506648A/ja active Pending
- 1996-05-29 CZ CZ973811A patent/CZ381197A3/cs unknown
- 1996-05-29 SK SK1595-97A patent/SK159597A3/sk unknown
- 1996-05-29 AU AU58824/96A patent/AU709196B2/en not_active Ceased
- 1996-05-29 EP EP96920553A patent/EP0828496A1/en not_active Withdrawn
- 1996-05-29 KR KR1019970708917A patent/KR19990022436A/ko not_active Ceased
- 1996-05-29 CA CA002222318A patent/CA2222318A1/en not_active Abandoned
- 1996-05-29 EA EA199700449A patent/EA000677B1/ru not_active IP Right Cessation
- 1996-05-29 EE EE9700308A patent/EE03306B1/xx not_active IP Right Cessation
- 1996-05-29 PL PL96323669A patent/PL323669A1/xx unknown
- 1996-05-29 BR BR9609020A patent/BR9609020A/pt not_active Application Discontinuation
- 1996-05-29 HU HU9900659A patent/HUP9900659A3/hu unknown
- 1996-05-29 NZ NZ308935A patent/NZ308935A/en unknown
- 1996-05-31 ZA ZA964465A patent/ZA964465B/xx unknown
1997
- 1997-11-19 IS IS4617A patent/IS4617A/is unknown
- 1997-11-20 BG BG102060A patent/BG63103B1/bg unknown
- 1997-12-01 NO NO975527A patent/NO975527L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP9900659A3 (en)	2002-12-28
HUP9900659A2 (hu)	2001-04-28
ZA964465B (en)	1996-12-11
AU5882496A (en)	1996-12-18
PL323669A1 (en)	1998-04-14
CN1192685A (zh)	1998-09-09
EE03306B1 (et)	2000-12-15
EP0828496A1 (en)	1998-03-18
TR199701482T1 (xx)	1998-03-21
AU709196B2 (en)	1999-08-26
EA199700449A1 (ru)	1998-06-25
NO975527D0 (no)	1997-12-01
BG102060A (en)	1998-07-31
CA2222318A1 (en)	1996-12-05
CZ381197A3 (cs)	1998-06-17
NO975527L (no)	1997-12-01
KR19990022436A (ko)	1999-03-25
JPH10506648A (ja)	1998-06-30
SK159597A3 (en)	1998-06-03
EA000677B1 (ru)	2000-02-28
IL118422A0 (en)	1996-09-12
WO1996038156A1 (en)	1996-12-05
NZ308935A (en)	2000-07-28
IS4617A (is)	1997-11-19
BR9609020A (pt)	1999-07-06

Publication	Publication Date	Title
JP2004531468A5 (ja)	2009-04-02
WO2016062283A1 (zh)	2016-04-28	抗发炎用药物在制备抑制癌症的医药组合物中的应用
EA000964B1 (ru)	2000-08-28	Способ лечения или предупреждения остеопороза
US5804570A (en)	1998-09-08	Method of lessening the risk of non-vertebral bone fractures
US20110166234A1 (en)	2011-07-07	Medicinal product and treatment
Tirado-Miranda et al.	2001	Septic arthritis due to Scedosporium apiospermum: case report and review
BG63103B1 (bg)	2001-04-30	Използуване на алендронат за профилактика на остеопороза
US20020169148A1 (en)	2002-11-14	Use of alendronate for the prevention of osteoporosis
CN109771424B (zh)	2021-03-16	一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用
AU713824B2 (en)	1999-12-09	Prevention of tooth loss by the administration of alendronate or its salts
KR19980702209A (ko)	1998-07-15	척추 골절의 위험을 경감시키는 방법
US20190224208A1 (en)	2019-07-25	Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
GB2197198A (en)	1988-05-18	Analgesic preparations
CN111821423A (zh)	2020-10-27	一种白介素2用于治疗慢性自发性荨麻疹的应用
EP3893880A1 (en)	2021-10-20	Methods for treating heterotopic ossification
TW201105332A (en)	2011-02-16	Agent for preventing forearm bone fracture which comprises eldecalcitol
Standard	2018	Pr TEVA-RISEDRONATE
Sack	2008	Fighting the fracture cascade: evaluation and management of osteoporotic fractures
Standard et al.	2017	Pr RISEDRONATE
EP0691814B1 (en)	2002-06-26	Method and composition for treatment of osteoporosis
Zahid et al.	2020	Efficacy of Bisphosphonates and Recombinant Parathyroid Hormone in Treatment of Osteoporosis in Pakistan
Marcinowska-Suchowierska et al.	2014	Pharmacological therapy of osteoporosis with bisphosphonates–for whom, what kind, and for how long?
Lindsay	1995	Secondary prevention of osteoporosis
Sharma et al.	2014	Alendronate and its role in post-menopausal osteoporosis
MXPA97009906A (en)	1998-10-15	Use of bisphosphonates to prepare compositions to prevent loss of associated bone conterapia immunosupres